Results 131 to 140 of about 36,119 (263)

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy

Acta Medica Iranica, 2017
Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders.
Stepan Kutilek
doaj  

Additional file 1: of Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

, 2018
Marcus Vetter, Julia Landin, Barbara M. Szczerba, Francesc Castro-Giner, Sofia Gkountela, Cinzia Donato, Ilona Krol, Ramona Scherrer, Catharina Balmelli, Alexandra Malinovska, Alfred Zippelius, Christian Kurzeder, Viola Heinzelmann‐Schwarz, William P. Weber, Christoph Rochlitz, Nicola Aceto   +15 more
openalex   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients [PDF]

Vittorio Fusco, Costanza Massarino, Maura Rossi, Alessio Gambino, Antonio Maconi, Paolo G. Arduino   +5 more
openalex   +1 more source

Review of: "DENOSUMAB-RELATED OSTEONECROSIS OF JAW (ONJ) VERSUS ZOLEDRONIC ACID-RELATED ONJ: DIFFERENT CHARACTERISTICS AT COMPUTED TOMOGRAPHY SCAN EVALUATION? A PROPOSAL FOR A MULTICENTRE STUDY"

, 2022
Ourania Nicolatou‐Galitis
openalex   +1 more source

O papel do osteoclasto na fisiopatologia de doenças do aparelho locomotor e na condição de alvo terapêutico [PDF]

, 2013
O osteoclasto é uma célula especializada, cuja principal função é a reabsorção óssea. Está envolvida na patogénese da osteoporose, da Doença de Paget e das metástases ósseas, entre outras.
Judas, F, Silva, P
core  

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk [PDF]

, 2011
Steven Boonen, Jonathan D. Adachi, Z. Man, Steven R. Cummings, Kurt Lippuner, Ove Törring, John C. Gallagher, Jordi Farrerons, A. Wang, Nathalie Franchimont, Javier San Martín, Andreas Grauer, Michael R. McClung   +12 more
openalex   +1 more source

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial [PDF]

, 2022
Ahmadreza Jamshidi, Mahdi Vojdanian, Mohsen Soroush, M. Akbarian, Mehrdad Aghaei, Asghar Hajiabbasi, Zahra Mirfeizi, Alireza Khabbazi, Gholam Hossein Alishiri, Anousheh Haghighi, Ahmad Salimzadeh, Hadi Karimzadeh, Fatemeh Shirani, Mohammad Reza Hatef Fard, Mohammad Ali Nazarinia, Soosan Soroosh, Nassim Anjidani, Farhad Gharibdoost   +17 more
openalex   +1 more source

Impact of Denosumab on Lower Extremity Surgery Rates in Charcot Foot

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Charcot foot is a catastrophic joint disease usually associated with diabetic peripheral neuropathy.
Gyan Narayan BS, Joshua Wang MS, William Weiss MD   +2 more
doaj   +1 more source

MO801SAFETY AND EFFICACY OF DENOSUMAB IN HEMODYALISED PATIENTS UP TO 48 MONTHS TREATMENT FOLLOW-UP [PDF]

, 2021
Rita Chiara Ierace, Alessandra Moioli, Francescaromana Festuccia, Claudia Fofi, Simona Barberi, Paolo Mené   +5 more
openalex   +1 more source